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Abstract
Varicella-zoster virus (VZV) causes chickenpox and shingles, and is found in human populations worldwide. The lack of
temporal signal in the diversity of VZV makes substitution rate estimates unreliable, which is a barrier to understanding
the context of its global spread. Here, we estimate rates of evolution by studying live attenuated vaccines, which evolved
in 22 vaccinated patients for known periods of time, sometimes, but not always undergoing latency. We show that the
attenuated virus evolves rapidly (~106 substitutions/site/day), but that rates decrease dramatically when the virus
undergoes latency. These data are best explained by a model in which viral populations evolve for around 13 days before
becoming latent, but then undergo no replication during latency. This implies that rates of viral evolution will depend
strongly on transmission patterns. Nevertheless, we show that implausibly long latency periods are required to date the
most recent common ancestor of extant VZV to an “out-of-Africa” migration with humans, as has been previously
suggested.
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Introduction
Varicella-zoster virus (VZV; also known as human herpesvirus
3) is a nuclear-replicating double-stranded DNA (dsDNA)
virus, with a genome of around 125 kb and over 70 open
reading frames. The virus is the causative agent of varicella
(chicken pox), and herpes zoster (shingles), two conditions
that can lead to serious complications (World Health
Organization 1998; Gilden et al. 2011).
The global genetic diversity of VZV is now well character-
ized, with five major clades segregating geographically (Muir
et al. 2002; Schmidt-Chanasit and Sauerbrei 2011; Grose 2012;
Zell et al. 2012; Chow et al. 2013). But although its phylogeny
is well resolved, there is less certainty about the age of VZV’s
most recent common ancestor, and this is a major impedi-
ment to understanding its origins and the ecological context
of its global spread.
For example, Zell et al. (2012) analyzed VZV along with
other alphaherpesvirinae (see also McGeoch and Cook 1994;
Muir et al. 2002; Grose 2012), and showed that the viral phy-
logeny agreed exactly with the phylogeny of their mammalian
hosts (Meredith et al. 2011), suggestive of host-virus cospeci-
ation. Calibration of the viral phylogeny with the mammalian
fossil record placed the most recent common ancestor of
VZV at approximately 110,000 years ago. This date is consis-
tent with the prominent theory that VZV spread around the
globe by accompanying humans on their out-of-Africa migra-
tions (Grose 1999, 2012; Petraglia et al. 2010)—a pattern also
observed in other pathogens (Moodley et al. 2012; Paraskevis
et al. 2013). In contrast, Firth et al. (2010) analyzed viruses
sampled from around the world over a 37-year period, and,
using a method of dated tips (Rambaut 2000), estimated that
the most recent common ancestor of VZV lived just 309 years
ago (95% highest posterior density [HPD] 51–741).
Such wildly different rate estimates have been remarkably
common in the study of viruses, suggesting that something is
severely wrong with our assumptions about their evolution
(Holmes 2003; Sharp and Simmonds 2011; Lythgoe and Fraser
2012). In fact, as the authors recognize, there are good reasons
to doubt both previous estimates for the age of VZV.
Specifically, Firth et al.’s (2010) method of dated tips relies
on data sets showing sufficient temporal signal, but despite
VZV samples obtained over 37 years, randomization of the
sampling dates provided similar estimates, suggesting that
true temporal signal was absent. In contrast, estimates
based on cospeciation have used a calibration point at ap-
proximately 24 million ybp (the Old World Monkey–ape split,
assumed to coincide with the divergence between Herpes
simplex and Macacine herpesvirus 1 [Zalmout et al. 2010]).
This calibration is over 200 times older than the date of in-
terest, which can cause problems, for example, with
 The Author 2015. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is
properly cited. Open Access
1020 Mol. Biol. Evol. 32(4):1020–1028 doi:10.1093/molbev/msu406 Advance Access publication January 6, 2015
 at U
niversity College London on June 18, 2015
http://m
be.oxfordjournals.org/
D
ow
nloaded from
 
saturation of informative sites (Linder et al. 2005; Duche^ne
et al. 2014). Furthermore, such analyses must rely on the
assumption that rates of viral evolution have remained
roughly constant over the entire 24-My period.
Another difficulty with dating viral origins is the time-
dependency of evolutionary rate estimates (Ho and Larson
2006; Ho et al. 2011; Sharp and Simmonds 2011; Lythgoe and
Fraser 2012). This may be a general phenomenon with several
causes (Ho et al. 2011), but one factor might be uniquely
important in viral evolution, namely viral latency, that is,
the ability of pathogenic viruses to lay dormant in the cell.
Indeed, several authors have suggested that long periods of
latency, with little or reduced viral replication, might reconcile
the observations of rapid rates of evolution over short periods
and the slower rates implied by plausible biogeographical
scenarios (Kelly 1994; Jenkins et al. 2002; Holmes 2003;
Switzer et al. 2005; Ramsden et al. 2008; Sharp and
Simmonds 2011; Lythgoe and Fraser 2012). This could be
an important factor in VZV evolution, as it undergoes periods
of latency in neurons (particularly in the trigeminal and dorsal
nerves). Indeed, herpes zoster is the result of viral reactivation
following latency (Gilden et al. 2011). But although compar-
ative evidence shows that viruses causing latent infection
evolve significantly more slowly than viruses with acute or
persistent infections (Hanada et al. 2004), we lack evidence
that latency is directly affecting evolutionary rates in any
single case.
Here, we take a novel approach to investigating the effects
of latency on evolutionary rates, by tracking the within-pa-
tient evolution of VZV vaccines (Depledge et al. 2013). The
vOka vaccine, which was developed in the 1970s (Takahash
et al. 1974), is a live attenuated virus. As such, it is free to
evolve in patients following their vaccination (Kanda et al.
2011; Quinlivan et al. 2011; Depledge et al. 2013). Vaccination
can also cause side effects in some cases. In particular, ap-
proximately 5% of vaccinated healthy children experience an
attenuated form of the varicella rash (Sharrar et al. 2000; Galea
et al. 2008; Goulleret et al. 2010), whereas a smaller number of
patients experience latent infection (zoster) as a direct result
of the vaccination (Civen et al. 2009).
Within-patient evolution of the VZV vaccine has attracted
attention because of its possible role in causing disease (e.g.,
following reversion toward the wild-type [Quinlivan et al.
2011; Depledge et al. 2013]), but the viral genomes also
allow us to study replicated instances of viral evolution over
a known time period. Because some of the vaccine genotypes
have established latency and reactivated before sampling,
the data also allow us to estimate the effects of latency on
evolutionary rates.
Results
Analysis of Vaccine Batches and Inference of the
Ancestral Sequence
To estimate the amount of evolutionary change that has
accrued in each patient, we must first infer the genome
sequence of the vaccine that was administered to that
patient. To this end, we compared whole-genome sequences
of different batches of the vOka vaccine (table 1). Specifically,
we compared three modern vaccine batches (obtained
between 2009 and 2012 in the United States and United
Kingdom), to an early batch from 1986. These vaccine batches
therefore approximately span the dates of our patient sam-
ples (1982–2013; table 1). In an alignment of over 100 kb, we
found no fixed differences between any of the vaccine strains,
and this remained true when we excluded polymorphic var-
iants segregating at frequencies below 10%.
This suggests that the process of culturing, by which vac-
cine batches are derived from a common frozen seed stock, is
not introducing substantial evolutionary change, and this sug-
gests that the sequences of the modern vaccine batches will
be very close to that administered to the patients. However,
all of the vaccine batches did contain genetic variation (sup-
plementary table S1, Supplementary Material online), and so
variable vaccine sequences are likely to have been injected
into patients (Depledge et al. 2013). Failure to account for
such variation could upwardly bias our estimates of evolu-
tionary rates (Nei 1971), although the extent of such an
artifact will depend on the profile of the genetic variation
within the vaccine.
Table 1. Samples used in this study.
Sample Type Sequencer Date Days Passage Acc. No.
VVAG Vaccine MiSeq 2009* — — KF558383
VV10 Vaccine MiSeq 2010 — — KF558384
VV12 Vaccine MiSeq 2012 — — KF558385
B86 Vaccine HiSeq 1986* — — KF853225
A171B Varicella GAiix 1988* 14 High KF853226
A182B Varicella GAiix 1988* 16 High KF558381
A185B Varicella GAiix 1988* 21 High KF558382
O27 Varicella GAiix 1999* 16 None KF558376
VR2 Varicella MiSeq 2007 17 None KF558372
VR1 Varicella MiSeq 2007 14 None KF558373
R43 Varicella MiSeq 2000* 23 None KF853229
VR5 Varicella MiSeq 2008 16 None KF853233
R3 Zoster GAiix 1999* 244 Low KF853228
R52 Zoster GAiix 1999* 490 Low KF853230
T17 Zoster GAiix 2000* 310 Low KF558378
T25 Zoster GAiix 2000* 547 Low KF558379
v76 Zoster GAiix 1982* 630 Low KF558380
K11 Zoster MiSeq 1997* 75 None KF558391
L53 Zoster MiSeq 1997* 131 None KF558389
T61 Zoster GAiix 2001* 91 None KF558377
ZR1 Zoster MiSeq 2006 330 None KF558371
Q27 Zoster MiSeq 1998* 541 Low KF853227
ZR2 Zoster MiSeq 2006 150 None KF853231
ZR3 Zoster MiSeq 2007 577 None KF853232
ZR4 Zoster MiSeq 2010 517 None KF853234
ZR5 Zoster MiSeq 2013 120 None KF853235
NOTE.—Type, either vaccine batch, patient samples from a vaccine varicella rash or
vaccine zoster rash; Date, year of vaccine batch production or year of vaccination;
Days, time interval between vaccination and rash development; Passage, rates of lab
passaging prior to sequencing; Acc. No., GenBank accession numbers of consensus
sequence.
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The bias will be weakest if the genetic variation in the
vaccines mostly comprises deleterious mutations. Such vari-
ation should contribute little to within-patient evolution, as
deleterious mutations segregate at low frequencies, but rarely
reach fixation. Previous results suggest that most variation in
VZV vaccines is indeed deleterious (Depledge et al. 2013), and
so for our major analyses, we used the consensus sequence
of the three modern vaccine batches as our assumed
ancestral genome.
However, a stronger bias would arise if some of the injected
variants were selectively neutral or beneficial once inside the
patient (Depledge et al. 2013). Accordingly, to minimize the
effects of ancestral polymorphism, we repeated all analyses
using only sites that were fixed in all four vaccine batches
(including the early batch). Of course, this approach might
still miss very low frequency variants, but such variants are
expected to have the least effect on rate estimates, essentially
because low frequency variants are likely to have arisen only
a few viral replications before vaccination (Nei 1971).
A far larger artifact could arise if secondary infections with
VZV were mistakenly interpreted as populations that derived
from the vaccine. To exclude this possibility, we confirmed
that each sample was more closely related to the vOka vac-
cine strain than to any published genome of wild-type VZV
(Zell et al. 2012), and that all carried the diagnostic single
nucleotide polymorphisms reported by (Quinlivan et al.
2011). As the vaccine was originally derived from naturally
occurring VZV of East Asian origin (Takahash et al. 1974), the
patient samples were particularly distantly related to naturally
occurring strains from the United States and United
Kingdom, where our samples were collected (Kanda et al.
2011; Quinlivan et al. 2011; Zell et al. 2012; Chow et al.
2013; Depledge et al. 2013).
As a final check, we also tested for shared variants between
the patient samples, as genuine postvaccination evolution
would proceed independently in each patient. We found
that the majority of variants observed (118/176 = 67%) were
present in no more than a single patient, whereas 95% of the
variants were present in fewer than 5 of the 22 strains. This is
consistent with our assumption that the evolutionary
changes we inferred were indeed accrued after vaccination
(see also below).
Evolutionary Rates in Patients Who Developed
Varicella Rashes
For each of our 22 patient samples, we know the length of
time between vaccination and sampling of VZV genomes
from the resulting rash (table 1). By comparing the genomes
from these samples to the (inferred) sequence of the initial
vaccine, we estimated the rate of evolution of the attenuated
virus within the patient.
First, consider the eight samples from patients who devel-
oped a varicella rash, and thus were sampled before any viral
latency (table 1). Rate estimates can be misled by the inclu-
sion of low frequency polymorphic variants in the patient
samples, because these can represent sequencing errors, or
mildly deleterious polymorphisms, which violate the assump-
tions of our rate estimator (e.g., Eyre-Walker 2002; see also
supplementary material, Supplementary Material online).
Accordingly, we obtained maximum-likelihood estimates
with polymorphisms excluded below a range of cut-off fre-
quencies. These estimates are shown in the left-hand panel of
figure 1. Rate estimates are clearly substantially higher when
polymorphic variants segregating at 5% or below were in-
cluded in the analysis. This is consistent with evidence that
low frequency variants are often sequencing errors (Depledge
et al. 2013; supplementary fig. S1, Supplementary Material
online). In contrast, estimates were very stable at cut-off fre-
quencies of 10% or above and consistently suggested a rate of
approximately 6.36 106 substitutions/site/day (CIs: 5.22–
7.70 106; all rates here and below are reported with the
10% cut-off, unless otherwise specified). Furthermore, rate
estimates for all the patient samples were similar (supplemen-
tary fig. S2a, Supplementary Material online), and there was
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FIG. 1. Estimated rates of evolution for the eight VZV strains sampled from patients that had developed varicella rashes after vaccination (table 1). All
rates are maximum-likelihood estimates with confidence intervals obtained from the likelihood surface. The left-hand panel shows results varying the
allele cut-off frequency (denoted c in the supplementary methods, Supplementary Material online), that is, alleles found below the indicated frequency
in any single sample were removed from the analysis. The right-hand panel shows how results were affected by removing the three strains that were
subjected to passaging in the laboratory (black circles); and by removing any site that was polymorphic in any of the four vaccine batches (triangles). The
gray symbols show estimated rates for synonymous changes (empty symbols) and nonsynonymous changes (filled symbols) in protein coding genes.
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no evidence of significant between-patient rate variation
(Likelihood Ratio Test, ln L= 13.28, df = 7, P= 0.07). The
constancy of the rate estimates between patients gives us
some confidence that the estimates are not being greatly
inflated by genetic variation in the vaccine samples, as this
artifact would yield a constant amount of apparent evolution,
rather than a constant rate, implying a steady increase in
evolutionary change with time.
To further determine the robustness of our estimates, we
carried out several additional analyses. First, we reestimated
the rate after excluding three samples (A171B, A182B, and
A185B; table 1) that had been subject to extensive laboratory
passaging prior to sequencing. Estimates were little changed
(fig. 1), suggesting that neither passaging nor the use of the
older GaIIX sequencing technology for some of the samples
(table 1) was greatly affecting estimates once low frequency
variants were removed (Depledge et al. 2013).
Second, we repeated estimates excluding any site that was
found to be polymorphic in any of our four vaccine batches.
This is a much more conservative approach to accounting for
genetic variation in the vaccine (see above). However, the
procedure is also likely to artifactually decrease estimates,
by excluding sites under low levels of selective constraint,
and so most likely to contribute to evolution. Whatever the
cause, including only fixed vaccine sites decreased estimates
more than 3-fold to 1.71 106 substitutions/site/day (CIs:
1.17–2.43 106; fig. 1); and again there was no evidence of
variation in rate between patients (ln L= 1.66, df = 7,
P= 0.97).
Finally, estimates of evolutionary rates over short time pe-
riods might be inflated by the inclusion of mutations that are
under weak purifying selection, and so unlikely to contribute
to evolution over longer time periods (Ho et al. 2011). To test
for ineffective purifying selection, we repeated both analyses
estimating rates for synonymous and nonsynonymous
changes in protein-coding genes (gray symbols in fig. 1).
Rates were faster than the genomic average at synonymous
sites and slower at nonsynonymous sites, which is consistent
with greater levels of purifying selection acting on amino acid
changing mutations. And although dn/ds ratios are high (0.59
for all vaccine sites and 0.32 at fixed vaccine sites), they are
similar to estimates from the global diversity of VZV (poste-
rior median dn/ds = 0.31, 95% HPD 0.25–0.38; see below), sug-
gesting that purifying selection is effective, despite the short
time periods (Ho and Larson 2006).
Evolutionary Rates in Patients Who Developed Zoster
Results are radically altered when analyses were repeated with
the 14 samples from patients who developed herpes zoster
(i.e., where vaccine genotypes had undergone latency prior to
sampling). Although the qualitative patterns in the data were
similar (supplementary fig. S3, Supplementary Material
online), the single best-fit rate was between 1 and 2 orders
of magnitude slower (~3.18 107 substitutions/site/day
with all sites included or ~1.09 107 substitutions/site/
day with fixed vaccine sites only). Furthermore, there was
very strong evidence of rate variation between patients
(ln L= 150.89, df = 13, P< 106), and estimates from
individual patients varied from 1.10 107 to 2.07 106
substitutions/site/day (see supplementary fig. S2b,
Supplementary Material online).
Most notably, in contrast to the varicella samples (fig. 2a),
the estimated rates of evolution for the zoster samples
decreased linearly with the length of time between vaccina-
tion and the appearance of symptoms (fig. 2b). This pattern
suggests that the variable rates are due to similar amounts of
evolution taking place in each patient, despite the very dif-
ferent times between vaccination and the appearance of
herpes zoster. Indeed, model selection with the Bayesian
Information Criterion (BIC) suggests that a model with a
fixed amount of evolution provides a substantially better fit
to the zoster patient data than a model with a fixed rate of
evolution or a model with variable rates (BIC values: Single
amount 193.8, single rate 318.2, variable rates 219.6).
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FIG. 2. Estimated rates of evolution (substitutions/site/day) for each of
the 22 strains of VZV sampled from vaccinated patients. Estimated rates
are plotted against the length of time (days) between vaccination and
sampling, which followed the appearance of symptoms. Panel (a) shows
the eight patients who developed varicella rashes, with the horizontal
line showing the maximum-likelihood rate for the whole data set. Panel
(b) shows the 14 patients who developed herpes zoster rashes, with a
line with a slope of 1, suggesting that the amount, but not the rate, of
evolution is roughly constant in all strains.
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A natural interpretation for these results is that, following
vaccination, the attenuated virus evolves for a fixed amount
of time either before and/or after establishing a latent infec-
tion. Once latent, replication is arrested so that no new mu-
tations accumulate, regardless of the period of time spent
within the host. If this interpretation is correct, then we can
estimate this “duration of active viral replication” directly
from our data, by assuming that all 22 of our samples evolved
at the same rate when they were active (see supplementary
material, Supplementary Material online). Taking all 14 zoster
samples together, we estimate this duration to be t*= 13.3
days (CIs: 10.9–15.9; individual estimates range between 2.9
and 27.6 days).
Latency and Dating the Most Recent Common
Ancestor of VZV’s Global Diversity
Results above show that changes in viral latency periods can
substantially alter evolutionary rates. This implies that rates
estimated over very short-term periods might not be reliable
if extrapolated back to the origins of VZV. It also questions
dates inferred from the complete alphaherpesvirinae phylog-
eny, which assume that rates remained roughly constant for
millions of years before the origin of VZV.
Accordingly, to investigate the global spread of VZV we
reanalyzed published whole-genome data, representing the
global diversity of the virus (Zell et al. 2012). Because these
data were sampled over a 44-year period (1964–2008; see
supplementary table S2, Supplementary Material online),
temporal signal in the data might be used to date the phy-
logeny (Rambaut 2000; Firth et al. 2010). If rates of evolution
were relatively constant over the sampling period, then we
would expect earlier samples to have undergone less molec-
ular evolution. However, analyses reported in the supplemen-
tary material, Supplementary Material online, found no
evidence of such a pattern (see also Firth et al. 2010), sup-
porting our suggestion that variation in transmission patterns
can lead to erratic rate variation in VZV over short time
periods.
Because past transmission patterns are unknown to us, it is
difficult to date the spread of VZV with much certainty.
However, we can ask whether a hypothesized date of the
most recent common ancestor is consistent with plausible
transmission dynamics.
To do this, we first identified segments of the VZV genome
with no evidence of recombination (supplementary fig. S5,
Supplementary Material online), and then reconstructed the
evolutionary history of these segments using Bayesian phylo-
genetics, and a relaxed molecular clock. To constrain the
evolutionary rate of VZV in these analyses, we used the fol-
lowing equation, which relates short- and long-term rates (i.e.,
rates with and without latency effects).
mlong ¼
mshortt

avg: time between infections
; ð1Þ
where the numerator is the expected amount of evolutionary
change accrued while the virus is replicating, and the denom-
inator is the expected time between infections (including
both replication and latency periods). We then made several
assumptions to bias our analysis toward an older date esti-
mate: 1) We used the slower of our short-term rate estimates
(mshort = 1.71 106; fig. 1), obtained by excluding any site
that was polymorphic in the vaccine; 2) we used the lower
bound of our estimate of the duration of active viral replica-
tion (t* = 10.9 days); 3) we assumed an average 50-year gap
between transmissions, which is consistent with some ob-
served latency periods (Yawn et al. 2007; Weitzman et al.
2013), but ignores the possibility of varicella-to-varicella trans-
missions which occur without latency; and 4) we applied our
long-term rate solely to third positions in protein-coding
genes, thereby allowing other sites in the genome to evolve
more slowly.
Results of our dating analyses are shown in figure 3.
The phylogenies indicate the major clades of VZV, as identi-
fied by Zell et al. (2012) (see also supplementary fig. S5,
Supplementary Material online), and each phylogeny applies
to a different segment of the VZV genome, together com-
prising approximately 85% of its total length. The phyloge-
netic topologies of the two genomic segments differ
substantially, suggesting that they have recombined since
the origins of the virus (McGeoch and Cook 1994; Loparev
et al. 2007; Zell et al. 2012). However, the estimated dates of
the most recent common ancestors are remarkably similar
(segment 1: 4,904 ybp; segment 2: 4,880 ybp). Most impor-
tantly, despite our biasing results toward older date estimates,
both dates are significantly younger than the youngest pos-
sible dates for the out-of-Africa migrations of modern
humans (Petraglia et al. 2010).
To confirm this, we repeated our analyses, making no as-
sumptions about long-term rate, but constraining the most
recent common ancestor of VZV to 110,000 ybp—the date
obtained by Zell et al. (2012), which would be consistent with
the out-of-Africa hypothesis. This analysis estimated an aver-
age long-term rate of 3.74 107 substitutions/site/year.
With the foregoing assumptions about short-term rates, a
long-term rate this slow would require an average between-
transmission time of 1,112 years—which is clearly implausible.
Discussion
We have studied the evolution of the VZV vaccine within
patients. Using the unique biology of VZV, and the availability
of a well-characterized live attenuated vaccine, we have
shown that viral latency halts the molecular evolution of
the virus. This, to our knowledge, is the first direct evidence
that latency can reduce evolutionary rates in a single virus
species (Holmes 2003; Hanada et al. 2004; Switzer et al. 2005;
Sharp and Simmonds 2011; Lythgoe and Fraser 2012).
We have also provided a rate estimate for the vaccine in
the absence of latency effects. At approximately 103 substi-
tutions per site per year (~106 per site per day), our esti-
mates are congruent with some estimates from dsDNA phage
(Minot et al. 2013), but are around ten times faster than
typical short-term evolutionary rates of dsDNA viruses, as
inferred from dated tips dating of between-patient data (sup-
plementary fig. S7, Supplementary Material online). It is pos-
sible that viral latency is one cause of this discrepancy, as
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latency might have occurred in many published viral data
sets, but has certainly not occurred for patients who devel-
oped varicella rashes following vaccination.
Together, our results have implications for understand-
ing VZV biology. In particular, the strong effect of latency
on rates implies that VZV does not return to latency fol-
lowing activation, despite the asymptomatic shedding of
VZV in saliva (Nagel, Choe, Cohrs, et al. 2011), and the
presence of mRNA transcripts involved in replication in
latent cells (Nagel, Choe, Traktinskiy, et al. 2011;
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Genome segment 2 
Genome segment 1 VIII 
5 
IX 
IX 
3 
2 
4 
1 
1 
3 
VIII 
5 
4 
2 
FIG. 3. Dated phylogeny of the global diversity of VZV. Shown are Maximum Clade Consensus phylogenies for two large segments of the viral genome
that show no evidence of within-segment recombination. Node labels show posterior support values, and red bars represent 95% Credible Intervals on
the estimated divergence dates. The labeled clades of VZV (Zell et al. 2012) each appeared with 100% posterior support. Results were obtained after
making several conservative assumptions about the evolutionary rate of VZV, nevertheless, the date estimates are substantially younger than is implied
by the out-of-Africa hypothesis of VZV origins.
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Ouwendijk et al. 2012). This failure to return to latency is a
probable contrast to herpes simplex virus, a related human
alphaherpesvirus (Wilson and Mohr 2012), and is consis-
tent with the hypothesis that replication in the skin or
blood is needed for VZV to travel to the nerves (Nagel,
Choe, Cohrs, et al. 2011).
Our results also have implications of understanding VZV
evolution. First, the effects of latency imply that variation in
patterns of transmission will lead directly to variation in evo-
lutionary rates within and between VZV lineages. Evidence
suggests that VZV transmission does indeed vary greatly
across the world (Yawn et al. 2007; Nichols et al. 2011;
Weitzman et al. 2013), and might differ substantially between
modern and hunter-gatherer societies. Second, fundamental
differences in transmission biology imply that rates of evolu-
tion could vary substantially between the alphaherpesvirinae,
even when their mutation rate per replication is very similar.
Together, this implies that standard methods of molecular
dating—whether based on serially sampled genomes or host-
virus cospeciation—may be unreliable when applied to global
VZV diversity.
Despite this uncertainty, we have argued that the ex-
isting data on latency and short-term rates do not sup-
port the out-of-Africa scenario for the global spread of
VZV (Muir et al. 2002; Petraglia et al. 2010; Grose 2012;
Zell et al. 2012). Even making very conservative assump-
tions, our date estimates for the most recent common
ancestor of VZV were substantially younger than required
by the out-of-Africa hypothesis (fig. 3). Of course, this
conclusion relies on short-term rates estimated during
vaccinations, and not from natural transmission chains
involving the wild-type virus. Indeed, the only existing
rate estimates from a natural transmission chain (from
an outbreak in 2000 in Guinea-Bissau, Western Africa)
are substantially slower than our vaccine estimates, and
instead, are more typical of estimates from other dsDNA
viruses (Depledge et al. 2014; supplementary fig. S7,
Supplementary Material online). Nevertheless, even with
these slower short-term rates (and assuming that no la-
tency was involved in this transmission chain), implausibly
large periods of latency would be required to generate the
very slow long-term rate (~107 substitutions/site/year)
required by the out-of-Africa hypothesis (Zell et al.
2012; supplementary figs. S4 and S7, Supplementary
Material online).
As such, although VZV might well have been present
in ancestral African populations, its existing global distribu-
tion is unlikely to be explained by patterns of migration
from those populations. Instead, current evidence points to
a more recent global spread. This possibility is consistent
with the topologies shown in figure 3 (where clade 5,
which is primarily of African origin [Schmidt-Chanasit
and Sauerbrei 2011], is not basal in either tree), and with
evidence that aerosol transmission has led to the spread of
the virus through single countries over very short periods
of time (Hawrami et al. 1997; Quinlivan et al. 2002;
Sauerbrei et al. 2011).
Materials and Methods
Patient Samples and Genome Sequencing
The samples for this study are listed in table 1, and were
obtained from healthy children in the community who
were sampled as part of the postsurveillance vaccine studies
carried out in the United States (see Sharrar et al. 2000; Galea
et al. 2008) and Europe (see Goulleret et al. 2010). Ten of the
samples (B86, A171B, R43, VR5, R3, R52, Q27, ZR2, ZR3, ZR4,
and ZR5) are new to this study, whereas the remaining 16
were previously described (Depledge et al. 2013). Full details of
sequencing library preparation, sequencing, and variant call-
ing are given in the supplementary material, Supplementary
Material online.
Counting Fixed and Polymorphic Differences
To infer the ancestral vaccine sequence, we used two
approaches. First, we generated a consensus sequence of
the three modern vaccine strains (VVAG, VV10, and VV12;
table 1), after excluding all low frequency variants (cut-off
frequency 35%) present in each of the samples. Four sites
which contained a high frequency variant in all three vaccine
batches were excluded from the analysis. Second, we gener-
ated a vaccine sequence that excluded any site that was poly-
morphic at frequency 2% or above in any of the four vaccine
batches (table 1); this led to the exclusion of 221 sites. For the
patient samples, we used a variety of cut-off allele frequencies
(see below). After excluding low frequency variants, sites were
scored as polymorphic within the patient if they carried mul-
tiple bases, and as fixed differences within the patient if the
base(s) differed from that in the ancestral vaccine sequence.
All counts of polymorphic and fixed differences are contained
in supplementary table S1, Supplementary Material online.
Maximum-Likelihood Rate Estimation
Rates of evolution are most easily estimated from a single pair
of alleles, but each of our patient samples represents a genet-
ically variable population of virions. Methods to estimate evo-
lutionary rates in such cases can be derived from standard
population genetics theory, using the joint expectations of
the number of polymorphic differences in a sample of alleles,
and the number of fixed differences that separate this sample
from a known outgroup (Nei 1971; Welch 2006; Depledge
et al. 2011). However, existing methods of this kind assume
that a known number of alleles have been sequenced, which
is not the case with viral samples from patients. As such, to
analyze our data, we have developed a new maximum-likeli-
hood estimator of evolutionary rates, which assumes that the
number of alleles sampled is large, but unknown, and that
variants were excluded below a certain threshold frequency.
This method has been implemented in freely available open-
source software (see supplementary material, Supplementary
Material online, for full details).
Molecular Dating of VZV Global Diversity
To investigate the origin of VZV, we reanalyzed publicly
available complete genome sequences (see supplementary
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table S2, Supplementary Material online, and references
therein). For results reported, we retained all 49 published
genomes, but results were qualitatively unaltered when anal-
yses were repeated excluding samples derived from the vOka
vaccine stock (Acc. Nos. AB097932 and DQ008354–5), and
highly passaged isolates (Acc. Nos. DQ479962–3) (Tyler et al.
2007; Zell et al. 2012). The complete set of genomes yielded an
alignment of 126,632 bp with 1,049 segregating sites. Given
strong evidence of recombination in VZV (McGeoch and
Cook 1994; Loparev et al. 2007; Schmidt-Chanasit and
Sauerbrei 2011; Zell et al. 2012), we used phylogenetic tests
to identify segments of the VZV genome that appear to have
evolved over a single genealogy (Kosakovsky Pond et al. 2006).
To date the origin of each genomic segment, we used the
Bayesian phylogenetics package BEAST v. 1.7 (Drummond
et al. 2012). Full details of the priors and models used in
these phylogenetic analyses are given in the supplementary
material, Supplementary Material online.
Supplementary Material
Supplementary material, methods, figures S1–S7, and tables
S1 and S2 are available at Molecular Biology and Evolution
online (http://www.mbe.oxfordjournals.org/).
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